HomeDelivery PlatformHuman ProductsBusiness DevelopmentClinzGard NS


aMilanaPharm is a privately held specialty pharmaceutical company built upon a proprietary drug delivery platform capable of delivering a large number of active compounds.  The platform, TRI-726, can deliver actives from several hours to several days.

MilanaPharm’s focus is on developing pharmaceutical products within the chronic wound management segment. We strive to improve patient quality of life and reduce opioid dependence and addiction with effective alternatives for healing and pain.

Our immediate commitment to our shareholders is to maximize our existing drug delivery platform through innovative and effective products. Our long-term commitment is to help solve tomorrow’s drug delivery needs by continually creating better delivery technologies.



  • 01.09.2017
  • Hammock Pharmaceuticals Announces the Licensing of Women's Health and Urological Technology Platform from MilanaPharm

    read more